Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) Net income
Bio-Techne Corp's net income for fiscal 2026 was $181.9M, up 147.8% from $73.4M in fiscal 2025. Over the past ten years it has ranged from $73.4M (fiscal 2025) to $285.4M (fiscal 2023); the current reading is higher than 75% of that period. Bio-Techne Corp ranks 24th of 612 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | $181.9M | 147.77% |
| FY2025 | $73.4M | (56.34%) |
| FY2024 | $168.1M | (41.11%) |
| FY2023 | $285.4M | 8.49% |
| FY2022 | $263.1M | 88.49% |
| FY2021 | $139.6M | (39.12%) |
| FY2020 | $229.3M | 138.67% |
| FY2019 | $96.1M | (23.84%) |
| FY2018 | $126.2M | 65.80% |
| FY2017 | $76.1M | (27.17%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $54.6M | 7.00% |
| Mar 2026 | $51.0M | 34.30% |
| Dec 2025 | $38.0M | (0.46%) |
| Sep 2025 | $38.2M | — |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $241.5M |
| TECH Bio-Techne Corp | $181.9M |
| BMRN BioMarin Pharmaceutical Inc. compare | $73.0M |
| CORT Corcept Therapeutics Incorporated compare | $55.2M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$325.1M |
| BBIO BridgeBio Pharma, Inc. compare | −$702.0M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TECH
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement